Ceftriaxone for Amyotrophic Lateral Sclerosis
Introduction <table class="infobox infobox-therapeutic">Category </td>Target Indication </td>Mechanism </td>Company </td>Clinical Phase </td>
...
Ceftriaxone for Amyotrophic Lateral Sclerosis
Introduction <table class="infobox infobox-therapeutic">Category </td>Target Indication </td>Mechanism </td>Company </td>Clinical Phase </td>
Ceftriaxone For Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mechanism of Action Ceftriaxone is a third-generation cephalosporin antibiotic that was repurposed for ALS based on its ability to upregulate the excitatory amino acid transporter 2 (EAAT2) . EAAT2 (also known as GLT-1) is the primary glutamate transporter in the brain and is responsible for clearing glutamate from the synaptic cleft.
Key Molecular Properties
Primary target : EAAT2/GLT-1 glutamate transporterMechanism : Transcriptional upregulation of EAAT2 expressionAdditional effects : Anti-inflammatory, anti-oxidant propertiesFormulation : Intravenous or intramuscular administrationClinical Development
Phase I Studies
Established safety and tolerability in healthy volunteers
Demonstrated CNS penetration at therapeutic doses
No significant drug-drug interactions
Phase II Trial
Randomized, double-blind, placebo-controlled
Primary endpoint : Slow vital capacity (SVC) decline rateSecondary endpoints : ALSFRS-R progression, survivalShowed trend toward benefit in high-dose group
Phase III Trial (CLEVER Study)
Enrollment : 1,400 ALS patientsResult : Primary endpoint not met (negative)Findings : No significant difference in functional declinePost-hoc analysis : Suggested benefit in specific patient subgroupsRationale for ALS Treatment
Glutamate Excitotoxicity
ALS features excessive glutamate in the synaptic cleft
EAAT2 dysfunction leads to impaired glutamate clearance
Excitotoxicity causes motor neuron death
Riluzole (approved) works partially through this mechanism
Ceftriaxone's Advantages Over Riluzole
Therapeutic Implications
Why It Failed
Insufficient EAAT2 induction in human CNS at tolerable dosesTiming of intervention - patients too advancedALS heterogeneity - different subtypes respond differentlyEndpoint sensitivity - measurement issues
Lessons Learned
Need for biomarker-driven patient selection
Earlier intervention may be critical
Combination therapy approach warranted
EAAT2 remains a valid therapeutic target
Research Directions
Next-generation GLT-1 modulators with better CNS penetrationGene therapy approaches to increase EAAT2 expressionCombination trials with riluzole or other neuroprotective agentsBiomarker development for patient selection (CSF glutamate levels)
External Links
[ClinicalTrials.gov: Ceftriaxone ALS](https://clinicaltrials.gov/ct2/show/NCT00349674)
[Biogen ALS Pipeline](https://www.biogen.com)
[EAAT2 and Neuroprotection - Review](https://pubmed.ncbi.nlm.nih.gov)
See Also
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Riluzone](/therapeutics/riluzole)
[ Glutamate Excitotoxicity](/mechanisms/excitotoxicity)
[EAAT2](/proteins/eaat2-protein)
[ALS Therapeutics](/therapeutics/als-therapeutics)
This page was created on 2026-03-04
Research Directions Current research on ceftriaxone in ALS focuses on:
GLT-1 Upregulation : Maximizing glutamate transporter expressionNeuroprotection : Understanding the full scope of protective mechanismsCombination Therapies : Synergy with other ALS therapeuticsClinical Development
Phase III trials demonstrated safety but inconclusive efficacy
Ongoing biomarker studies to identify responsive patient subgroups
Exploring higher dosing regimens
Mechanistic Studies
Beyond glutamate transport: effects on neuroinflammation
Astrocyte modulation and astrocyte-neuron communication
Mitochondrial function preservation
Combination Approaches
With Riluzole : Potential synergistic effectsWith Edaravone : Complementary mechanismsGene therapy combinations : Future directionsAnimal Models
SOD1 Transgenic Mice : Primary model for ALS research[C9orf72](/entities/c9orf72) Models : Understanding repeat expansion effectsAstrocyte-Specific Studies : GLT-1 expression in [astrocytes](/entities/astrocytes)Key Publications
Rothstein et al. 2005 : Ceftriaxone ALS trial design and rationaleNational Institutes of Health Clinical Trial : Efficacy and safety dataGLT-1 Biology : Understanding glutamate transport mechanisms
Pharmacokinetics and Pharmacology
Mechanism of Action Ceftriaxone exerts neuroprotective effects in ALS through multiple mechanisms:
Glutamate transport enhancement : Increases expression and function of excitatory amino acid transporter 2 (EAAT2/GLT-1)Reduced excitotoxicity : Lower extracellular glutamate reduces motor neuron deathAnti-inflammatory effects : Modulates microglial activationAntioxidant properties : Reduces oxidative stress in motor [neurons](/entities/neurons)
Pharmacokinetics
Clinical Evidence
Preclinical Studies
SOD1 mouse models : Ceftriaxone delayed disease onset and improved survivalIn vitro studies : Protected motor neurons from glutamate toxicityMechanism studies : Confirmed GLT-1 upregulation in astrocytesClinical Trials
Post-Hoc Analyses
Subgroup benefits : Some patients showed slower progressionBiomarker effects : Reduced CSF glutamate levelsSafety profile : Generally well-toleratedAdverse Effects and Safety
Common Side Effects
Serious Adverse Events
Gallbladder disease : Sludge and stones with long-term usePancreatitis : Rare but reportedAnaphylaxis : Rare allergic reactionsSuperinfection : C. difficile colitisDrug Interactions
Aminoglycosides : Potential nephrotoxicityWarfarin : Possible INR elevationCalcium-containing solutions : Precipitation riskCurrent Status and Future Directions
Why Previous Trials Failed
Insufficient CNS penetration : Drug may not reach therapeutic levelsTiming of intervention : Treatment may need to start earlierPatient selection : Biomarker-driven patient selection neededCombination therapy : Single-agent approaches may be insufficientOngoing Research
Novel formulations : Enhanced CNS deliveryCombination approaches : Multi-target therapiesBiomarker development : Patient selection markersGene therapy : Viral vector-based GLT-1 deliveryBackground The study of Ceftriaxone For Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
Pathway Diagram
Mermaid diagram (expand to render)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
Related Analyses:
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
[Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) 🔄
Show full description